Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Eli Lilly & Co ( (LLY) ) has provided an announcement.
On August 18, 2025, Eli Lilly & Co entered into an underwriting agreement with several financial institutions for the issuance and sale of various notes, including both floating and fixed rate notes, totaling approximately $6.71 billion in net proceeds. This financial maneuver, completed on August 20, 2025, is expected to strengthen the company’s financial position and potentially impact its strategic operations and market presence.
The most recent analyst rating on (LLY) stock is a Hold with a $700.00 price target. To see the full list of analyst forecasts on Eli Lilly & Co stock, see the LLY Stock Forecast page.
Spark’s Take on LLY Stock
According to Spark, TipRanks’ AI Analyst, LLY is a Neutral.
Eli Lilly & Co’s strong financial performance and positive earnings call are significant strengths, driving the overall score. However, high valuation and cash flow challenges present risks. The lack of technical analysis data limits the assessment of market trends.
To see Spark’s full report on LLY stock, click here.
More about Eli Lilly & Co
Eli Lilly & Co is a pharmaceutical company known for developing and manufacturing a wide range of medications, focusing on areas such as oncology, immunology, and diabetes care.
Average Trading Volume: 4,382,794
Technical Sentiment Signal: Hold
Current Market Cap: $660.7B
For a thorough assessment of LLY stock, go to TipRanks’ Stock Analysis page.